{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T09:01:37Z","timestamp":1777453297659,"version":"3.51.4"},"reference-count":29,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"MSD Denmark Aps"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Therapy"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Molnupiravir (MOV) is an orally bioavailable ribonucleoside with antiviral activity against all tested SARS-CoV-2 variants. We describe the demographic, clinical, and treatment characteristics of non-hospitalized Danish patients treated with MOV and their clinical outcomes following MOV initiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>Among all adults (&gt;18\u00a0years) who received MOV between 16 December 2021 and 30 April 2022 in an outpatient setting in Denmark, we summarized their demographic and clinical characteristics at baseline and post-MOV outcomes using descriptive statistics. Outcomes were emergent hospitalization and all-cause mortality during the 28 days after MOV initiation. We estimated the odds ratios (OR) of outcomes by time from positive test to treatment using logistic regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 3691 MOV-treated patients, of whom 45.8% were male and mean age was 70.1 years. Most patients (76.2%) initiated MOV within 0\u20132 days after a positive SARS-CoV-2 test and 16.8% within 3\u20135 days. Over a 28-day period, rates for all-cause, respiratory- or COVID-19-related, and COVID-19-related hospitalization were 4.8%, 2.6% and 1.5%, respectively. All-cause mortality was 1.6%. Initiation of MOV 3\u20135 days after a positive SARS-CoV-2 test compared to 1\u20132 days was associated with an increased risk of all-cause (OR 1.85, 95% CI 1.29\u20132.67) and respiratory or COVID-19-related (OR 1.78, 95% CI 1.07\u20132.94) hospitalization, and all-cause mortality (OR 2.90, 95% CI 1.64\u20135.15).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>MOV was primarily prescribed to vaccinated elderly persons with multiple comorbidities. The all-cause hospitalization and mortality rates in this population were low. Early initiation of MOV reduced the risk of hospitalization and death compared with late initiation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/13596535241313244","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T11:32:26Z","timestamp":1737459146000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical outcomes among COVID-19 patients initiated on molnupiravir in Denmark \u2013 A national registry study"],"prefix":"10.1177","volume":"30","author":[{"given":"Carsten S","family":"Larsen","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Aarhus University Hospital, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8991-8559","authenticated-orcid":false,"given":"Caroline L","family":"Westergaard","sequence":"additional","affiliation":[{"name":"VIVE The Danish Center for Social Science Research, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina B","family":"St\u00e6rke","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Aarhus University Hospital, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Urs","family":"Arnet","sequence":"additional","affiliation":[{"name":"Center for Observational and Real-world Evidence (CORE), MSD GmBH Innovation, Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gui","family":"Liu","sequence":"additional","affiliation":[{"name":"Center for Observational and Real-world Evidence (CORE), Merck & Co, Inc, Rahway, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Line R","family":"Kants\u00f8","sequence":"additional","affiliation":[{"name":"MSD Denmark ApS, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakob","family":"Kjellberg","sequence":"additional","affiliation":[{"name":"VIVE The Danish Center for Social Science Research, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,1,21]]},"reference":[{"key":"bibr1-13596535241313244","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0234765"},{"key":"bibr2-13596535241313244","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1419"},{"key":"bibr3-13596535241313244","first-page":"22","volume":"39","author":"Sharma K","year":"2021","journal-title":"Paediatr Respir Rev"},{"key":"bibr4-13596535241313244","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00662-4"},{"key":"bibr5-13596535241313244","doi-asserted-by":"publisher","DOI":"10.3390\/metabo13020309"},{"key":"bibr6-13596535241313244","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116044"},{"key":"bibr7-13596535241313244","first-page":"5","volume":"2","author":"Tiang F","year":"2023","journal-title":"Internatinal Journal of Antimicrobial Agents"},{"key":"bibr8-13596535241313244","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2022.06.059"},{"key":"bibr9-13596535241313244","unstructured":"Danish Health Authority. Pr\u00e6paratanmeldelse Lagevrio (molnupiravir). 2021. Available at: https:\/\/www.sst.dk\/-\/media\/Udgivelser\/2021\/Corona\/Tabletbehandling\/Praeparatanmeldelse-Lagevrio.ashx?sc_lang=da&hash=5958AF0A0FE94663F9DE08C0FBDC6EE3 (accessed 6 June 2023)."},{"key":"bibr10-13596535241313244","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijregi.2022.12.005"},{"key":"bibr11-13596535241313244","unstructured":"European Centre for Disease Control. The European Respiratory Virus Surveillance Summary. 2023. Available at: https:\/\/www.ecdc.europa.eu\/en\/covid-19\/country-overviews (accessed 11 June 2023)."},{"key":"bibr12-13596535241313244","first-page":"m3379","volume":"370","author":"Nyberg T","year":"2020","journal-title":"BMJ"},{"key":"bibr13-13596535241313244","unstructured":"Statens Serum Institut. Historiske Covid-19 opg\u00f8relser. 2023. Available at: https:\/\/www.ssi.dk\/sygdomme-beredskab-og-forskning\/sygdomsovervaagning\/c\/historiske-covid-19-opgoerelser (accessed 14 August 2023)."},{"key":"bibr14-13596535241313244","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34442"},{"key":"bibr15-13596535241313244","unstructured":"The Conversation. Paxlovid is Australia\u2019s first-line COVID antiviral but Lagevrio also prevents severe disease in over-70s. 2022. Available at: https:\/\/theconversation.com\/paxlovid-is-australias-first-line-covid-antiviral-but-lagevrio-also-prevents-severe-disease-in-over-70s-195349 (accessed 11 June 2023)."},{"key":"bibr16-13596535241313244","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvacx.2023.100391"},{"key":"bibr17-13596535241313244","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00507-2"},{"key":"bibr18-13596535241313244","first-page":"2","volume":"29","author":"Arbel R","year":"2022","journal-title":"Research Square"},{"key":"bibr19-13596535241313244","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02597-1"},{"key":"bibr20-13596535241313244","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12020393"},{"key":"bibr21-13596535241313244","unstructured":"Malin JJ, Weibel S, Gruell H, et al. Efficacy and safety of molnupiravir for the the treatment of SARS-CoV-2 infection: a systematic review and metaanlysis."},{"key":"bibr22-13596535241313244","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac781"},{"key":"bibr23-13596535241313244","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2118542"},{"key":"bibr24-13596535241313244","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116846"},{"key":"bibr25-13596535241313244","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2023.02.012"},{"key":"bibr26-13596535241313244","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-022-00809-7"},{"key":"bibr27-13596535241313244","doi-asserted-by":"publisher","DOI":"10.3390\/v15030811"},{"key":"bibr28-13596535241313244","unstructured":"The Danish Health Authority. Sundheds\u00adstyrelsen anbefaler ikke l\u00e6ngere Lagevrio til behandling af covid-19. 2023. Available at: https:\/\/www.sst.dk\/da\/nyheder\/2023\/sundhedsstyrelsen-anbefaler-ikke-laengere-lagevrio-til-behandling-af-covid19 (accessed 12 June 2023)."},{"key":"bibr29-13596535241313244","first-page":"m3379","volume":"370","author":"Argawal A.","year":"2020","journal-title":"BMJ"}],"container-title":["Antiviral Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13596535241313244","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/13596535241313244","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13596535241313244","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:53:23Z","timestamp":1777380803000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/13596535241313244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,21]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1177\/13596535241313244"],"URL":"https:\/\/doi.org\/10.1177\/13596535241313244","relation":{},"ISSN":["1359-6535","2040-2058"],"issn-type":[{"value":"1359-6535","type":"print"},{"value":"2040-2058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,21]]},"article-number":"13596535241313244"}}